TCGA-05-5428-01A-01R-1628-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 57
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.510
- ADIPOGENESIS+0.330
- FATTY_ACID_METABOLISM+0.310
- MYC_TARGETS_V1+0.310
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.290
- SPERMATOGENESIS+0.230
- DNA_REPAIR+0.220
- PANCREAS_BETA_CELLS+0.220
- MTORC1_SIGNALING+0.210
- BILE_ACID_METABOLISM+0.200
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.560
- WNT_BETA_CATENIN_SIGNALING-0.510
- MITOTIC_SPINDLE-0.480
- UV_RESPONSE_DN-0.360
- PI3K_AKT_MTOR_SIGNALING-0.280
- APICAL_JUNCTION-0.270
- G2M_CHECKPOINT-0.260
- TGF_BETA_SIGNALING-0.260
- MYOGENESIS-0.240
- ESTROGEN_RESPONSE_EARLY-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-35-5375-01A-01R-1628-07 | — | cohortA1 | 0.865 |
| 2 | TCGA-66-2778-01A-02R-0851-07 | — | cohortSQ1 | 0.830 |
| 3 | SRR27320676 | — | — | 0.819 |
| 4 | TCGA-66-2771-01A-01R-0980-07 | — | cohortSQ1 | 0.815 |
| 5 | 57901dc3-9b2f-4271-8dd9-8fc0121d6971 | — | — | 0.804 |
| 6 | TCGA-37-4133-01A-01R-1100-07 | — | cohortSQ1 | 0.800 |
| 7 | 6f2c5313-1c83-46c7-a15c-5b9526c1763b | — | — | 0.798 |
| 8 | 131a9973-dfc9-4897-8c19-d5c43cecba0a | — | — | 0.792 |
| 9 | TCGA-22-4594-01A-01R-1201-07 | — | cohortA3 | 0.788 |
| 10 | TCGA-38-4631-01A-01R-1755-07 | — | cohortA4 | 0.787 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.510 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.330 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.310 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.310 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.290 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.230 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.220 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.220 | Cobimetinib | — uncovered |
| MTORC1_SIGNALING | 0.210 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.190 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.170 | Idelalisib | — uncovered |
| PEROXISOME | 0.160 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.140 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.130 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.070 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.060 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.060 | Inavolisib | — uncovered |